https://orcid.org/0000-0003-3817-6696
Abstract
Background
Mucous membrane pemphigoid (MMP), a rare autoimmune vesiculous and erosive disorder, may affect multiple mucous membranes, with the oral cavity being the most commonly affected site. Its treatment depends on the site(s) of mucosal involvement and disease severity.
Patients and Methods
A 62-year-old female patient with MMP that predominantly involved the oral cavity strongly rejected systemic corticosteroid or immunosuppressive agents and was successfully treated with abrocitinib, a highly selective JAK-1 inhibitor with a good safety profile.
Results
The case demonstrated good efficacy and safety profile of abrocitinib for the treatment of MMP with predominant oral involvement.
Conclusion
Abrocitinib is a promising agent for the treatment of MMP with oral involvement.
Data Sharing Statement
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
Ethics Statement
The publication of images was included in the patient’s consent for publication of the case. The Hospital Ethics Committees of the Affiliated People’s Hospital of Hangzhou Medical College approved publishing the case details.
Consent Statement
The authors have obtained the patient’s consent to publish photographs. The patient in this manuscript has given written informed consent to the publication of his case details.
Acknowledgments
We thank Bullet Edits Limited for the linguistic editing and proofreading of the manuscript.
Disclosure
The authors declare that they have no conflicts of interest and no payment for expert testimony for this work.